{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:27:22Z","timestamp":1772252842752,"version":"3.50.1"},"reference-count":25,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"JSPS KAKENHI","award":["22K12887"],"award-info":[{"award-number":["22K12887"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Romidepsin is an important therapeutic option for patients with peripheral T-cell lymphoma (PTCL). However, the timing of romidepsin administration remains controversial. The objective of this study was to characterize the safety and efficacy of romidepsin as consolidation therapy after gemcitabine, dexamethasone, and cisplatin (GDP) therapy (GDPR). This study of patients treated between March 2019 and March 2021 was registered with the Japan Registry of Clinical Trials (registration number: jRCT0000000519). If complete response, partial response, or stable disease was confirmed after 2\u20134 GDP cycles, romidepsin was administered every 4 weeks for 1 year. Seven patients with relapsed\/refractory (R\/R) PTCL (T-follicular helper phenotype [n = 1] and angioimmunoblastic T-cell lymphoma [n = 6]) were included in this prospective study (PTCL-GDPR). After a median follow-up of 34 months of patients in PTCL-GDPR, the 2-year overall survival rate was 71%, and the overall response rate after treatment was 57%. Common adverse events in patients with PTCL-GDPR included hematological toxicities such as neutropenia, which improved with supportive treatment. There were no treatment-related mortalities. GDPR might be safe and effective in elderly transplant-ineligible patients with R\/R PTCL; however, further investigation is required.<\/jats:p>","DOI":"10.3390\/hematolrep16020034","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T13:32:55Z","timestamp":1716903175000},"page":"336-346","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Phase II Trial of Romidepsin as Consolidation Therapy after Gemcitabine, Dexamethasone, and Cisplatin in Elderly Transplant-Ineligible Patients with Relapsed\/Refractory Peripheral T-Cell Lymphoma"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6143-7906","authenticated-orcid":false,"given":"Satoshi","family":"Yamasaki","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Kyushu University Beppu Hospital, 4546 Tsurumihara, Tsurumi, Beppu 874-0838, Japan"},{"name":"Department of Hematology, Clinical Research Institute, NHO Kyushu Medical Center, Fukuoka 810-0065, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroatsu","family":"Iida","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Research, NHO Nagoya Medical Center, Nagoya 460-0001, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Hematology, NHO Shibukawa Medical Center, Shibukawa 377-0204, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morio","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, NHO Shibukawa Medical Center, Shibukawa 377-0204, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Department of Hematology, NHO Hiroshimanishi Medical Center, Otake 739-0696, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Izumi","sequence":"additional","affiliation":[{"name":"Department of Hematology, NHO Sendai Medical Center, Sendai 983-8520, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3723-8445","authenticated-orcid":false,"given":"Akiko","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Research, NHO Nagoya Medical Center, Nagoya 460-0001, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2356-3725","authenticated-orcid":false,"given":"Hiroaki","family":"Miyoshi","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, Kurume University, Kurume 830-0011, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Ohshima","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, Kurume University, Kurume 830-0011, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Nagai","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Research, NHO Nagoya Medical Center, Nagoya 460-0001, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinical Research Institute, NHO Kyushu Medical Center, Fukuoka 810-0065, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"key":"ref_1","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., and Vardiman, J.W. (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00277-015-2468-y","article-title":"Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin(GDP) for patients with relapsed o rrefractory peripheral T-Cell lymphomas:A consortium for improving survival of lymphoma(CISL) trial","volume":"94","author":"Park","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00277-016-2877-6","article-title":"Gemcitabine, dexamethasone, Andcisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-Not otherwisespecified","volume":"96","author":"Qi","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s12185-017-2286-1","article-title":"Romidepsin in Japanese patients with relapsed or refractory peripheral T-Cell lymphoma. A phase I\/II and pharmacokinetics study","volume":"106","author":"Maruyama","year":"2017","journal-title":"Int. J. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1080\/10428194.2017.1295143","article-title":"Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: Analysis of two phase II trials","volume":"58","author":"Shustov","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood-2022-169336","article-title":"Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with Aggressive T-Cell Malignancies in a Phase I\/II Trial","volume":"140","author":"Hosing","year":"2022","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Stuver, R., and Moskowitz, A.J. (2023). Therapeutic Advances in Relapsed and Refractory Peripheral T-Cell Lymphoma. Cancers, 15.","DOI":"10.3390\/cancers15030589"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1080\/10428194.2020.1845336","article-title":"Comparison of prognostic scores in transplant-ineligible patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma: A retrospective study from the national hospital organization in Japan","volume":"62","author":"Yamasaki","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"International Harmonization Project on Lymphoma Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_13","first-page":"469","article-title":"Phase II Trial Using Romidepsin after Gemcitabine, Dexamethasone, and Cisplatin Therapy in Elderly Transplant-Ineligible Patients with Relapsed\/Refractory Peripheral T-Cell Lymphoma: Study Protocol","volume":"73","author":"Yamasaki","year":"2019","journal-title":"Acta Med. Okayama"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/(SICI)1099-1611(199907\/08)8:4<355::AID-PON401>3.0.CO;2-I","article-title":"Development of quality of life questionnaire in Japan: Quality of life assessment of cancer patients receiving chemotherapy","volume":"8","author":"Kurihara","year":"1999","journal-title":"Psychooncology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0895-4356(98)00095-X","article-title":"Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan","volume":"51","author":"Fukuhara","year":"1998","journal-title":"J. Clin. Epidemiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13045-016-0266-1","article-title":"A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed\/refractory peripheral T-cell lymphoma patients","volume":"9","author":"Pellegrini","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.3324\/haematol.2018.192906","article-title":"Romidepsin enhances the efficacy of cytarabine in vivo, Revealing histonedeacetylase inhibition as apromising therapeutic strategy for KMT2Ar earranged infant acute lymphoblastic leukemia","volume":"104","author":"Cheung","year":"2019","journal-title":"Haematologica"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/CCO.0000000000000469","article-title":"New perspectives in the therapeutic approach of peripheral T-cell lymphoma","volume":"30","author":"Gisselbrecht","year":"2018","journal-title":"Curr. Opin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/bloodadvances.2021004269","article-title":"Impact of comorbidity in older patients with peripheral T-cell lymphoma: An international retrospective analysis of 891 patients","volume":"6","author":"Mead","year":"2022","journal-title":"Blood Adv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin Plus CHOP versus CHOP in Patients with Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.bbmt.2017.07.027","article-title":"Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK\/T cell lymphomas: An international collaborative effort on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation","volume":"23","author":"Kumar","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s12185-020-02879-w","article-title":"Effects of stem cell transplantation in patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma","volume":"112","author":"Yamasaki","year":"2020","journal-title":"Int. J. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: A multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/16\/2\/34\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:49:37Z","timestamp":1760107777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/16\/2\/34"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["hematolrep16020034"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep16020034","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3685901\/v1","asserted-by":"object"}]},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,28]]}}}